Loading...

TCRT ALAUNOS THERAPEUTICS INC Other Situations 8-K Filing

LNS

TCRT

ALAUNOS THERAPEUTICS INC

(TCRT)

2026 8-K

Preclinical Results Revealed

Preclinical Data Announcement

Delisting Notice

Positive Drug Data

Termination Notice

Settlement Agreement

Compliance Regained

Increase in authorized shares

Departures and Appointments

Equity Offerings

Equity Offerings

Equity Offerings

Director Resignation

Board Compensation

License Termination

Reverse Stock Split

Reverse Stock Split

Reverse Stock Split

Reverse Stock Split

Dismissal of Independent Re...

Annual Meeting Approval

Management Changes

Compliance regained with Na...

Reverse Stock Split

Reverse Stock Split

Appointment of Interim CEO

Appointment of Director and...

Management Changes

Resignation of Director

Management Departure

Financial Condition and Del...

Resignation and Appointment

Financial Results and Strat...

Voluntary Delisting

Annual Meeting Approval

Financial Results Announcement

License Agreement Amendment

Loan Agreement Amendment

Management Changes

Earnings Reports

Presentation and Press Release

External Links:

On May 26, 2026, Alaunos Therapeutics, Inc. announced findings from preclinical studies on ALN1003, their candidate for obesity treatments; results include data from previous reports dated March 2 and May 18, highlighting the drug's potential but emphasizing it has not been tested in humans yet.

AI Assistant

ALAUNOS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.